Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world data on palbociclib combo for breast cancer in japan

NCT ID NCT05399329

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked back at medical records of 693 Japanese patients with a certain type of advanced breast cancer (HR+/HER2-) who received palbociclib plus endocrine therapy as their first or second treatment. Researchers measured how long patients lived without the cancer getting worse and overall survival. The goal is to see how well this treatment works in everyday practice, not just in clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
palbociclib plus endocrine therapy
What this could lead to
If successful, this study could confirm that palbociclib plus endocrine therapy works well in real-world Japanese patients, supporting its continued use.
What could go wrong
This is a retrospective observational study, not a controlled trial, so results may be influenced by patient selection or missing data. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

  • Aichi Cancer Center

    Nagoya, 464-8681, Japan

  • Gifu University Hospital

    Gifu, 501-1194, Japan

  • Hiroshima University Hospital

    Hiroshima, 734-8551, Japan

  • Hokkaido Cancer Center

    Sapporo, Hokkaido, 003-0804, Japan

  • Ishikawa Prefectural Central Hospital

    Kanazawa, Ishikawa-ken, 920-8530, Japan

  • Japan Community Health care Organization Kurume General Hospital

    Kurume, Fukuoka, 830-0013, Japan

  • Jichi Medical University Hospital

    Shimotsuke, Tochigi, 329 0498, Japan

  • Kaizuka City Hospital

    Kaizuka, Osaka, 597-0015, Japan

  • Kitasato University Hospital

    Sagamihara, Kanagawa, 252-0329, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Hospital Organization Osaka National Hospital

    Osaka, 540-0006, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, 791-0280, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, 541-8567, Japan

  • Osaka University Hospital

    Suita, Osaka, 565-0871, Japan

  • Saitama Prefectural Cancer Center

    Kita-adachi-gun, Saitama, 362-0806, Japan

  • Seirei Hamamatsu General Hospital

    Hamamatsu, Shizuoka, 430-8558, Japan

  • Shizuoka Prefectural Hospital Organization

    Shizuoka, 420-8527, Japan

  • Showa University Hospital

    Tokyo, 142-8666, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, 980-8574, Japan

  • Tokai University Hospital

    Kanagawa, 259-1193, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.